Sekar Kathiresan - 10 Aug 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol
VERV
Transactions as of
10 Aug 2022
Net transactions value
-$1,425,500
Form type
4
Filing time
11 Aug 2022, 17:00:28 UTC
Previous filing
27 Jul 2022
Next filing
05 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $69,500 +50,000 +16% $1.39* 367,839 10 Aug 2022 Direct
transaction VERV Common Stock Sale $1,495,000 -50,000 -14% $29.90 317,839 10 Aug 2022 Direct F1
holding VERV Common Stock 240,997 10 Aug 2022 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 80,997 10 Aug 2022 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -50,000 -23% $0.000000 167,425 10 Aug 2022 Common Stock 50,000 $1.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
F2 The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.